StreetAlpha
13F holdings · Q3 2026

Pivotal bioVenture Partners Investment Advisor

San Francisco, CA · files as Pivotal bioVenture Partners Investment Advisor LLC
Know the moment Pivotal bioVenture Partners Investment Advisor filesYou follow Pivotal bioVenture Partners Investment Advisor An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 1844645

Pivotal bioVenture Partners Investment Advisor reported 14 stocks worth $252M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PCVX (32.2%), ARQT (10.6%) and TRVI (9.9%). Compared with Q2 2026, the fund opened new positions in OBX and BRVE, added to OCS, trimmed ARQT, AVLN and ZBIO and sold out of RXRX.

Latest filing: what Pivotal bioVenture Partners Investment Advisor did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
2 new1 added3 trimmed1 sold outBought about $19.6M · sold about $18.8M
New 2
Added 1
Trimmed 3
Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$252M−18.2% vs last quarter
Stocks held142 new · 1 sold out
Top 5 weight68.8%very concentrated
Turnover15%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PCVX
Vaxcyte Inc
$81.1M32.2%1.4MNo change8 of 8
2
ARQT
Arcutis Biotherapeutics Inc
$26.6M10.6%1M−257K (−20%)8 of 8
3
TRVI
Trevi Therapeutics Inc
$25M9.9%1.7MNo change6 of 8
4
AVLN
Avalyn Pharma Inc
$24.7M9.8%867K−100K (−10%)2 of 8
5
EVMN
Evommune Inc
$15.9M6.3%1.9MNo change4 of 8
6
IMNM
Immunome Inc
$15.8M6.3%733KNo change5 of 8
7
OCS
Oculis Holding AG
$15.5M6.2%1.7M+153K (+10%)8 of 8
8
OBX
Obsidian Therapeutics Inc
$11.8M4.7%860KNew position1 of 8
9
AVTX
Avalo Therapeutics Inc
$6.7M2.6%434KNo change3 of 8
10
BRVE
Braveheart Bio Inc
$6.4M2.5%317KNew position1 of 8
🔒 4 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
RXRX
Recursion Pharmaceuticals in
$2.2M596K

Reported value

last 8 quarters
$148MQ4 '24
$124MQ1 '25
$161MQ2 '25
$173MQ3 '25
$259MQ4 '25
$280MQ1 '26
$308MQ2 '26
$252MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Pivotal bioVenture Partners Investment Advisor 13F FAQ

What does Pivotal bioVenture Partners Investment Advisor own?

Pivotal bioVenture Partners Investment Advisor reported 14 stocks worth $252M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PCVX (32.2%), ARQT (10.6%) and TRVI (9.9%). The table above lists every position in the filing (the top 10 without an account).

What did Pivotal bioVenture Partners Investment Advisor buy and sell in Q3 2026?

Compared with Q2 2026: 2 new positions, 1 added to, 3 trimmed and 1 sold out. New positions include OBX and BRVE. It sold all of RXRX.

When will Pivotal bioVenture Partners Investment Advisor file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Pivotal bioVenture Partners Investment Advisor's portfolio worth?

The Q3 2026 filing reports $252M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.